We're sorry, but your browser is no longer supported.

To improve your experience on our site and ensure your security, please upgrade to a modern browser Google Chrome, Mozilla Firefox or Microsoft Edge.

For more information click here.

FOx BIOSYSTEMS raises €5.8 million in B-round financing to scale up its operations

Diepenbeek, Belgium, January 13th, 2023 – Fox BIOSYSTEMS announces today that
they successfully closed on their funding round, raising €5.8M in new capital. Investors in
this round are Heran Partners, LRM, The Gemma Frisius Fund, KU Leuven, and
NetScientific.

FOX BIOSYSTEMS has developed an innovative Surface Plasmon Resonance (SPR)
technology using optical sensors. Their product, the White FOx, combines a microfluidicsfree
dip-in protocol for fast and user friendly SPR sensing. The unique approach of the
White FOx eliminates the risk of clogging and cross-contamination when using complex
samples such as lysates, whole blood or large particles. The sensor probes are available
with several generic surface chemistries and can be switched easily to allow the detection
of different target molecules, including antibodies, nanobodies, microvesicles, phages and
large particles, all with a single lab device.

A wide range of applications make the White FOx the ideal option for any life science or
biopharmaceutical research lab. Kinetic affinity analysis, label free biomolecule
quantification and fast specific and ultra-sensitive sandwich assays are all possible and
uniquely facilitate analysis of complex unpurified samples.

The additional raised capital will be used to scale up the company’s operations, accelerate
the development of new application areas, and to boost the commercialization of this
unique system.

Thomas van Elzakker, CEO of FOx BIOSYSTEMS: “We are very happy with the strong
support of our investors for our highly motivated team in realizing our vision for FOx
BIOSYSTEMS. They are confidently investing in our fast commercial growth today, while
also enabling us to deliver on our exciting innovation roadmap for tomorrow. The White
FOx system offers a solution to many of today’s analysis challenges, and it will continue
to be key in revealing new data and helping scientists to reach their goals more quickly.”
Katleen Vandersmissen, PhD, Chair of FOx BIOSYSTEMS and Managing Partner of HERAN
Partners: “With HERAN we try to spot those technologies and teams that can make a
difference and positive impact within the domain of Life Sciences. We believe that FOx,
now strongly backed by this financing round and the recent EIC grant, is up for success
based on their innovative take and ease of use on complex samples.”

About FOx Biosystems
FOx BIOSYSTEMS is a Belgian company with a mission to revolutionize the life sciences
and pharmacological research market with innovative real-time, label-free analysis
products. The basis of their success is a novel fiber-optic-based SPR biosensor which
enables users to generate high-quality, cost-effective biomolecular data fast, and over a
wide range of applications.

For more information visit www.foxbiosystems.com

Contact:
Mr. Kris Ver Donck, VP Marketing & Applications
info@foxbiosystems.com

About Heran Partners
Heran Partners is a Belgian-based MedTech and Digital Health investment fund. The
HERAN HealthTech Fund I focuses on European HealthTech, providing venture & growth
capital accompanied by a strong network, expertise and mentorship to startups and scaleups
with an outstanding technology platform and market potential. We strive to have
impact.

More information: www.heranpartners.com or info@heranpartners.com

About LRM
LRM is an investment company that develops and stimulates economic growth in Limburg.
We provide a solid foundation, allowing companies and projects, which create jobs in
Limburg, to grow. Our financial means and economic expertise, together with Limburg’s
key assets, create a unique breeding ground.

More information: www.lrm.be or Jeroen Bloemen: j.bloemen@lrm.be

About Gemma Frisius Fund KU Leuven
Gemma Frisius Fund (GFF) is a seed capital fund, established in 1997 as a joint venture
between KU Leuven, KBC Private Equity and BNP Paribas Fortis Private Equity. It combines
the research and technology transfer expertise of the university with the financial and
investment expertise of the two financial partners. GFF provides seed capital in the early
development phases of innovative, research-based spin-off companies originating from all
technology domains and provides support in their further growth process.

More information: lrd.kuleuven.be/en/spinoff/gemma-frisius-fund

About KU Leuven
KU Leuven supports researchers and students in transforming their innovative ideas and
technologies into commercial products and services that impact people’s lives across the
globe. One way to do this is by creating spin-off companies, such as FOx BIOSYSTEMS.
Since 1972, 149 KU Leuven spin-offs were created, directly employing more than 7,000
people. In the period from 2005 to 2021, KU Leuven invested € 21.7 million in its spin-off
companies, and € 1.46 billion of external capital was raised.

More information: http://lrd.kuleuven.be/en/spinoff

About NetScientific plc

NetScientific plc (AIM: NSCI) is an investment and commercialisation group with an
international portfolio of innovative life science, sustainability and technology companies.
NetScientific identifies, invests in, and builds high growth companies in the UK and
internationally. The company adds value through the proactive management of its
portfolio, progressing to key value inflection points, and delivering investment returns
through partial or full liquidity events.